These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 15259481)

  • 1. Comparison of two single-day regimens of triclabendazole for the treatment of human pulmonary paragonimiasis.
    Calvopiña M; Guderian RH; Paredes W; Cooper PJ
    Trans R Soc Trop Med Hyg; 2003; 97(4):451-4. PubMed ID: 15259481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of human pulmonary paragonimiasis with triclabendazole: clinical tolerance and drug efficacy.
    Calvopiña M; Guderian RH; Paredes W; Chico M; Cooper PJ
    Trans R Soc Trop Med Hyg; 1998; 92(5):566-9. PubMed ID: 9861383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A clinical trial of triclabendazole in the treatment of human paragonimiasis skrjabini].
    Hu P; Liu YH
    Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2001; 19(5):305-7. PubMed ID: 12572050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triclabendazole in the treatment of Paragonimiasis skrjabini.
    Gao J; Liu Y; Wang X; Hu P
    Chin Med J (Engl); 2003 Nov; 116(11):1683-6. PubMed ID: 14642135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pulmonary paragonimiasis. Pediatric case report].
    Maticorena Agramonte VF; Ormeño Julca AJ; Coveñas Coronado CDP; Polar Córdova V; Belloso Rodríguez JA
    Arch Argent Pediatr; 2019 Dec; 117(6):e659-e663. PubMed ID: 31758906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triclabendazole for the treatment of fascioliasis and paragonimiasis.
    Keiser J; Engels D; Büscher G; Utzinger J
    Expert Opin Investig Drugs; 2005 Dec; 14(12):1513-26. PubMed ID: 16307491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized trial of a single, double and triple dose of 10 mg/kg of a human formulation of triclabendazole in patients with fascioliasis.
    Talaie H; Emami H; Yadegarinia D; Nava-Ocampo AA; Massoud J; Azmoudeh M; Mas-Coma S
    Clin Exp Pharmacol Physiol; 2004 Nov; 31(11):777-82. PubMed ID: 15566392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of two single-day regimens of triclabendazole for fascioliasis in Peruvian children.
    Maco V; Marcos L; Delgado J; Herrera J; Nestares J; Terashima A; Samalvides F; Gotuzzo E
    Rev Soc Bras Med Trop; 2015; 48(4):445-53. PubMed ID: 26312936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical field trials of praziquantel in pulmonary paragonimiasis due to Paragonimus uterobilateralis in endemic populations of the Igwun Basin, Nigeria.
    Udonsi JK
    Trop Med Parasitol; 1989 Mar; 40(1):65-8. PubMed ID: 2662354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experimental observation of effects of triclabendazole on Paragonimus westermani infection in dogs.
    Liu Y; Gao J; Wang X; Yu D; Su Q
    Chin Med J (Engl); 1999 Apr; 112(4):345-8. PubMed ID: 11593536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of triclabendazole on the lung fluke, Paragonimus uterobilateralis in the experimental host Sigmodon hispidus.
    Weber P; Büscher G; Büttner DW
    Trop Med Parasitol; 1988 Dec; 39(4):322-4. PubMed ID: 3067323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A paragonimiasis patient with allergic reaction to praziquantel and resistance to triclabendazole: successful treatment after desensitization to praziquantel.
    Kyung SY; Cho YK; Kim YJ; Park JW; Jeong SH; Lee JI; Sung YM; Lee SP
    Korean J Parasitol; 2011 Mar; 49(1):73-7. PubMed ID: 21461273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic effect of triclabendazole in patients with paragonimiasis in Cameroon: a pilot study.
    Ripert C; Couprie B; Moyou R; Gaillard F; Appriou M; Tribouley-Duret J
    Trans R Soc Trop Med Hyg; 1992; 86(4):417. PubMed ID: 1440821
    [No Abstract]   [Full Text] [Related]  

  • 14. Triclabendazole in the treatment of human fascioliasis: a community-based study.
    el-Morshedy H; Farghaly A; Sharaf S; Abou-Basha L; Barakat R
    East Mediterr Health J; 1999 Sep; 5(5):888-94. PubMed ID: 10983527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Albendazole therapy for experimentally induced Paragonimus kellicotti infection in cats.
    Dubey JP; Hoover EA; Stromberg PC; Toussant MJ
    Am J Vet Res; 1978 Jun; 39(6):1027-31. PubMed ID: 666077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pleuropulmonary paragonimiasis.
    McManus TE; Thomas M; Rogers D; Harrison A; Lewis C
    Intern Med J; 2009 Mar; 39(3):203. PubMed ID: 19383070
    [No Abstract]   [Full Text] [Related]  

  • 17. Administration of triclabendazole is safe and effective in controlling fascioliasis in an endemic community of the Bolivian Altiplano.
    Villegas F; Angles R; Barrientos R; Barrios G; Valero MA; Hamed K; Grueninger H; Ault SK; Montresor A; Engels D; Mas-Coma S; Gabrielli AF
    PLoS Negl Trop Dis; 2012; 6(8):e1720. PubMed ID: 22880138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A retrospective clinical analysis of pediatric paragonimiasis in a Chinese children's hospital from 2011 to 2019.
    Qian M; Li F; Zhang Y; Qiao Z; Shi Y; Shen J
    Sci Rep; 2021 Jan; 11(1):2005. PubMed ID: 33479468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of pulmonary paragonimiasis with a new broad-spectrum antihelmintic, praziquantel.
    Spitalny KC; Senft AW; Meglio FD; Moran J; Peter G
    J Pediatr; 1982 Jul; 101(1):144-6. PubMed ID: 7086613
    [No Abstract]   [Full Text] [Related]  

  • 20. Single dose therapy of paragonimiasis with menichlopholan.
    Nwokolo C; Volkmer KJ
    Am J Trop Med Hyg; 1977 Jul; 26(4):688-92. PubMed ID: 889010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.